Loading...
Loading...
EWTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 40.4M |
| Operating I/L | -40.4M |
| Other Income/Expense | 6.3M |
| Interest Income | 6.3M |
| Pretax | -34.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -34.1M |
Edgewise Therapeutics, Inc. is a biopharmaceutical company specializing in the development of small molecule therapies for musculoskeletal diseases. Their lead product candidate, EDG-5506, is an orally administered small molecule designed to target the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. The company has completed Phase 1 clinical trials for this product. Edgewise Therapeutics focuses on developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
